EX-10.2



 





Exhibit 10.2




Brian J. G. Pereira, M.D. Joins Biodel’s Board of Directors




DANBURY, Conn., November 21, 2007 —Biodel, Inc. (Nasdaq: BIOD) today announced the addition of
Brian J.G. Pereira, M.D., to its Board of Directors.



Dr. Pereira is the President and CEO of AMAG Pharmaceuticals, Inc., a biopharmaceutical company
dedicated to the development and commercialization of therapeutic and diagnostic products. At
AMAG Pharmaceuticals, Dr. Pereira played an integral role in advancing the company’s key product
candidate, Ferumoxytol, towards marketing approval with the U.S. Food and Drug Administration.



“Brian brings an incredible wealth of knowledge to Biodel from his years of experience in the
biotechnology and medical community,” said Dr. Solomon Steiner, CEO and Chairman of Biodel. “As we
grow our company and advance our clinical products, Brian’s insights and perspectives will be
invaluable. We are excited and honored he has chosen to serve on Biodel’s Board of Directors.”



“Sol and his team have done an excellent job in advancing the clinical development of their lead
product candidate, VIAjectTM,” said Dr. Pereira. “I have been particularly impressed with the
company’s commitment to developing novel insulin treatments for the diabetes population. I look
forward to working with Biodel’s great board members who have guided this Company’s development.”



Prior to joining AMAG Pharmaceuticals, Dr. Pereira served as President and CEO of New England
Health Care Foundation, an independent 501(c)(3) corporation that employs staff physicians at
Tufts-New England Medical Center. Dr. Pereira has also held various other positions at Tufts-New
England Medical Center, including Interim Chief Operating Officer, Senior Vice President and
Executive Director, Vice Chairman for Strategic Development in the Department of Medicine and Staff
physician in the Division of Nephrology.



Dr. Pereira is a nationally recognized expert on kidney disease and has served on the editorial
board of twelve scientific journals. He is the editor of the widely read textbook, “Chronic Kidney
Disease, Dialysis and Transplantation,” and has over 200 scientific papers to his credit. Dr.
Pereira is Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program, a member of the
Board of Directors of Satellite Health Care and the National Kidney Foundation, and an advisor to
several other organizations. Dr. Pereira is a graduate of both St. John’s Medical College and Post
Graduate Institute of Medical Education and Research in India. He received his M.B.A. from Kellogg
Graduate School of Management at Northwestern University.



 









 





Exhibit 10.2




About Biodel Inc.




Biodel Inc. is a specialty biopharmaceutical company focused on the development and
commercialization of innovative treatments for endocrine disorders, such as diabetes and
osteoporosis. Biodel’s product candidates are developed by using VIAdelTM technology, which
reformulates existing FDA-approved peptide drugs. The Company’s lead product candidate, VIAjectTM,
is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or
Type 2 diabetes. VIAjectTM is currently being tested in two pivotal Phase III clinical trials.
Biodel’s pipeline also includes VIAtabTM, a sublingual tablet formulation of insulin in Phase I
clinical trials and two osteoporosis product candidates in pre-clinical studies. For further
information regarding Biodel, please visit the Company’s website at http://www.biodel.com.



Safe Harbor




This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements, other then statements of historical facts,
including statements regarding our strategy, future operations, future financial position, future
revenues, projected costs, prospects, plans and objectives of management are forward-looking
statements. The words “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,”
“may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” and similar
expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. The Company’s forward-looking statements are subject
to a number of known and unknown risks and uncertainties that could cause actual results,
performance or achievements to differ materially from those described or implied in the
forward-looking statements, including, but not limited to, our ability to secure FDA approval for
our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our
ability to market, commercialize and achieve market acceptance for product candidates developed
using our VIAdelTM technology; the progress or success of our research, development and clinical
programs, the initiation and completion of our clinical trials, the timing of the interim analyses
and the timing or success of our product candidates, particularly VIAjectTM and VIAtabTM; our ability
to secure additional patents for VIAjectTM and our other product candidates; our ability to protect
our intellectual property and operate our business without infringing upon the intellectual
property rights of others; our estimates of future performance; our ability to enter into
collaboration arrangements for the commercialization of our product candidates and the success or
failure of those collaborations after consummation, if consummated; the rate and degree of market
acceptance and clinical utility of our products; our commercialization, marketing and manufacturing
capabilities and strategy; our estimates regarding anticipated operating losses, future revenues,
capital requirements and our needs for additional financing; and other factors identified in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any
obligation to update any forward-looking statements as a result of events occurring after the date
of this press release.



 









 





Exhibit 10.2




BIOD-G




Contact:




Investors, should contact Clay A. Kramer, ckramer@burnsmc.com, or Media, Carney Noensie,
cnoensie@burnsmc.com, both of Burns McClellan, Inc., +1-212-213-0006, for Biodel Inc.



###